Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses

Completed 119 enrolled Changhai Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to compare the safety and efficacy of SBRT in LAPC with different biological effective dose (BED) (\<70Gy Vs.\>70Gy ) , to identify a dose range that could achieve better survival benefit and minimize the toxicity of radiotherapy.

Timeline

Start: 2020-11-10
Primary completion: 2025-08-15
Completion: 2025-08-15

Publications

Ye Y, Zhu X, Zhao X, Jiang L, Cao Y, Zhang H. Biologically effective doses of 60-70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a single-centre, phase II clinical trial. BMJ Open. 2022 Aug 29;12(8):e049382. doi: 10.1136/bmjopen-2021-049382.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Background	Paclitaxel	Small molecule	125 mg/m2	Intravenous

Indications

No indication recorded.